{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477861554
| IUPAC_name = 4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0]nona-2,7,9-triene-9-carboxamide
| image = Temozolomide structure.svg
| width = 160
| image2 = Temozolomide-3D-spacefill.png
| width2 = 160

<!--Clinical data-->
| tradename = Temodar, Temodal, Temcad
| Drugs.com = {{drugs.com|monograph|temozolomide}}
| MedlinePlus = a601250
| licence_EU = yes
| licence_US = Temozolomide
| pregnancy_AU =  
| pregnancy_US = D
| legal_AU =  
| legal_US = Rx-only
| legal_status = ℞-only
| routes_of_administration = Oral, intravenous

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 15%
| metabolism = spontaneously hydrolyzed at physiologic pH to the active species, 3-methyl-(triazen-1-yl)imidazole-4-carboxamide (MTIC) and to temozolomide acid metabolite
| elimination_half-life = 1.8 hours

<!--Identifiers-->
| IUPHAR_ligand = 7301
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 85622-93-1
| ATC_prefix = L01
| ATC_suffix = AX03
| ATC_supplemental =  
| PubChem = 5394
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00853
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5201
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = YF1K15M17Y
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D06067
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 72564
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 810

<!--Chemical data-->
| C=6 | H=6 | N=6 | O=2
| molecular_weight = 194.151 g/mol
| smiles = O=C(c1ncn2C(=O)N(\N=N/c12)C)N
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BPEGJWRSRHCHSN-UHFFFAOYSA-N
| melting_point = 212
| melting_notes =（分解）
}}
{{medical}}
'''替莫唑胺'''是一种口服[[化疗|化疗]]药物（屬於[[烷基化剂|烷基化剂]]），用于治疗某些脑癌，如成人恶性[[神经胶质瘤|神经胶质瘤]]和恶性[[黑色素瘤|黑色素瘤]]。该药物由英國伯明翰[[阿斯顿大学|阿斯顿大学]]的教授{{link-en|马尔寇姆史蒂文斯|Malcolm Stevens}}帶領的团队研發成功。<ref name=Sansom>{{cite journal | first = Clare | last = Sansom | name-list-format = vanc | journal = Chemistry World | date = July 2009 | pages = 48–51 | url = http://www.rsc.org/images/TEMOZOLOMIDE_ChemistryWorldJul09_tcm18-155909.pdf | title = Temozolomide – birth of a blockbuster }}</ref><ref>{{cite web | archive-url = https://web.archive.org/web/20120314043035/http://info.cancerresearchuk.org/cancerandresearch/progress/cancer_drugs/drug_discovery/temozolomide/ | archive-date = 14 March 2012 | dead-url = yes | url = http://info.cancerresearchuk.org/cancerandresearch/progress/cancer_drugs/drug_discovery/temozolomide/ | title = Malcolm Steven – interview | work = Cancer Research UK impact & achievements page}}</ref><ref name="pmid9189180">{{cite journal | vauthors = Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C | title = Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials | journal = Cancer Treatment Reviews | volume = 23 | issue = 1 | pages = 35–61 | date = January 1997 | pmid = 9189180 | doi = 10.1016/S0305-7372(97)90019-0 }}</ref>它自1999年8月在美国上市以来便可购得，2000年以後開始在其他国家上市。

==参考文献==
{{reflist}}
{{化疗药物}}
[[Category:DNA复制抑制剂|Category:DNA复制抑制剂]]
[[Category:胚胎毒物|Category:胚胎毒物]]
[[Category:前药|Category:前药]]
[[Category:先靈葆雅|Category:先靈葆雅]]
[[Category:致畸原|Category:致畸原]]
[[Category:癌症治療|Category:癌症治療]]
[[Category:1999年|Category:1999年]]
[[Category:内酰胺|Category:内酰胺]]
[[Category:氨甲酰|Category:氨甲酰]]
[[Category:咪唑四嗪|Category:咪唑四嗪]]